Journal article
Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
Blood cancer journal (New York), Vol.9(12), pp.102-7
12/13/2019
DOI: 10.1038/s41408-019-0263-z
PMCID: PMC6910906
PMID: 31836698
Abstract
High-sensitivity mass spectrometry assays are available to detect monoclonal immunoglobulins. To better assess the prevalence of monoclonal gammopathy of undetermined significance (MGUS), we identified 300 patients diagnosed with MGUS or related gammopathy who had a prior negative work-up for monoclonal proteins as part of the Olmsted County MGUS screening study. Two mass spectrometry-based detection methods (matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) and monoclonal immunoglobulin rapid accurate mass measurements (miRAMM) along with traditional immunofixation were performed on the Olmsted baseline and MGUS diagnostics serum samples. Among the 226 patients considered negative for MGUS based on protein electrophoresis and serum-free light-chain assay, a monoclonal protein could be detected at baseline in 24 patients (10.6%) by immunofixation, 113 patients (50%) by MADLI-TOF mass spectrometry, and 149 patients (65.9%) by miRAMM mass spectrometry. In addition, using miRAMM, some patients demonstrated an oligoclonal to monoclonal transition giving insight into the origin of MGUS. Using the sensitive miRAMM, MGUS is present in 887 of 17,367 persons from the Olmsted County cohort, translating into a prevalence of 5.1% among persons 50 years of age and older. This represents the most accurate prevalence estimate of MGUS thus far.
Details
- Title: Subtitle
- Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
- Creators
- David Murray - Mayo ClinicShaji K Kumar - Division of Hematology, Mayo Clinic, Rochester, MN 55906, USA.Robert A Kyle - Mayo ClinicAngela Dispenzieri - Division of Hematology, Mayo Clinic, Rochester, MN 55906, USA.Surendra Dasari - Mayo ClinicDirk R Larson - Division of Biostatistics, Mayo Clinic, Rochester, MN, 55906, USA.Celine Vachon - Mayo Clinic in FloridaJames R Cerhan - Mayo Clinic in FloridaS Vincent Rajkumar - Division of Hematology, Mayo Clinic, Rochester, MN 55906, USA.
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York), Vol.9(12), pp.102-7
- DOI
- 10.1038/s41408-019-0263-z
- PMID
- 31836698
- PMCID
- PMC6910906
- NLM abbreviation
- Blood Cancer J
- ISSN
- 2044-5385
- eISSN
- 2044-5385
- Grant note
- P50 CA186781 / NCI NIH HHS R01 CA168762 / NCI NIH HHS R01 CA107476 / NCI NIH HHS
- Language
- English
- Date published
- 12/13/2019
- Academic Unit
- Epidemiology
- Record Identifier
- 9984368225302771
Metrics
10 Record Views